Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Progressive Visuospatial Problems in a 71-Year-Old Man
Neurol 83:e6-e10, Symmonds, M.,et al, 2014
Early Child Development and Exposure to Antiepileptic Drugs Prenatally and Through Breastfeeding
JAMA Neurol 70:1367-1374, Veiby, G.,et al, 2013
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Child Development Following In Utero Exposure: Levetiracetam vs Sodium Valproate
Neurol 76:383-389, Shallcross,R.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Memantine Induces Reversible Neurologic Impairment in Patients with MS
Neurol 72:1630-1633, Villoslada,P.,et al, 2009
Reversible Cerebral Vasoconstriction Syndrome
Pract Neurol 9:256-267, Ducros,A. &Bousser,M.-G., 2009
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Acute Disseminated Encephalomyelitis
Arch Neurol 62:1673-1680, Menge,T.,et al, 2005
Dementia with Lewy Bodies
Lancet 362:1689-1690, Wilcock,G.K., 2003
Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
Valproate Embryopathy in Three Sets of Siblings: Further Proof of Hereditary Susceptibility
Neurol 59:630-633, Malm,H.,et al, 2002
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Near-Fatal Heat Stroke During the 1995 Heat Wave in Chicago
Ann Int Med 129:173-181, Damatte,J.E.,et al, 1998
Valproic Acid Hepatic Fatalities. III. U. S. Experience Since 1986
Neurol 46:465-469, Bryant,A.E.&Dreifuss,F., 1996
Progressive Deterioration of Intellect and Motor Function Occurring Several Decades after Cranial Irradiation
ARch Neurol 53:814-818, Duffey,P.,et al, 1996
The Eosinophilia-Myalgia Syndrome:Status of 205 Patients and Results of Treatment 2 Years After Onset
Ann Int Med 122:851-855, Hertzman,P.A.,et al, 1995
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
The Toxic Effects of Anticonvulsant Drugs in Long-Term Treatment of Epilepsy
JNNP 52:1116, Raman,R.,et al, 1989
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
A 54-year-old woman with Dementia, Myoclonus, and Ataxia
Neurol 89:e7-e12, Ali, F.,et al, 2017
Maternal Use of antiepileptic Agents During Pregnancy and Major Congenital Malformations in Children
JAMA 318:1700-1701, Bromley, R.L.,et al, 2017
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014
Valproic Acid Monotherapy in Pregnancy and Major Congenital Malformations
NEJM 362:2185-2193, Jentink,J., et al, 2010
Intrauterine Exposure to Carbamazepine and Specific Congenital Malformations: Systematic Review and Case-Control Study
BMJ 341:c6581, 1229, Jentik,J.,et al, 2010
Cognitive Function at 3 Years of Age After Fetal Exposure to Antiepileptic Drugs
NEJM 360:1597-1605,1667, Meador,K.J.,et al, 2009
Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Arch Neurol 66:865-869, Orr,C.F. &Ahlskog,E., 2009
CNS Complications of Radiotherapy and Chemotherapy
Lancet 374:1639-1651, Soussain,C.,et al, 2009
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
A 60-Year-Old Woman with Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA 300:1566-1574,1598, Ellison,J.M., 2008
Exposure to Antipsychotics and Risk of Stroke: Self Controlled Case Series Study
BMJ 337:616-618,586, Douglas,I.J. &Smeeth,L., 2008
A 75-Year-Old Man With Cognitive Impairment and Gait Changes, Lewy Body Disease
Neurol 69:1183-1189, Lippa,C.F.,et al, 2007
Delirium in Older Persons
NEJM 354:1157-1165, Inouye,S.K., 2006
Major Congential Malformations After First-Trimester Exposure to ACE Inhibitors
NEJM 354:2443-2451,2498, Cooper,W.O.,et al, 2006
Reversible Dementia with Parkinsonian Features Associated with Budesonide Use
Neurol 67:723, Proda,C.I.,et al, 2006
Atypical Antipsychotics in the Elderly with Parkinson Disease and the "Black Box" Warning
Neurol 67:564-566, Friedman,J.H., 2006
Atypical Antipsychotic Drugs and Risk of Ischaemic Stroke: Population Based Retrospective Cohort Study
BMJ 330:445-448, Gill,S.S., et al, 2005
Lamotrigine and the Risk of Malformations in Pregnancy
Neurol 64:955-960, 938, Cunnington, M. , et al, 2005